Merck Coronavirus Pill Sparks Calls for Distribution to Lower Income Countries

An experimental COVID-19 treatment pill called molnupiravir being developed by Merck & Co Inc and Ridgeback Biotherapeutics LP, is seen in this undated handout photo released by Merck & Co Inc and obtained by Reuters May 17, 2021. Merck & Co Inc/Handout via REUTERS

The plan to roll out Merck & Co’s (MRK.N) promising antiviral pill to treat COVID-19 risks repeating the inequities of vaccine distribution, potentially leaving the nations with the greatest need once again at the back of the line, international health groups say.

Click here to read more.

SOURCE: Reuters – Reporting by Justin Makangara, Benoit Nyemba and Stanis Bujakera; Additional reporting and writing by Hereward Holland; Editing by Bate Felix and Mike Harrison